Tagworks Pharmaceuticals Announces Clinical Study Approval for TGW211 in Treating HER2+ Tumors#Netherlands#Nijmegen#Tagworks_Pharmaceuticals#HER2+_Cancer#TGW211
Tagworks Pharmaceuticals Announces Clinical Study Approval for TGW211 in Treating HER2+ Tumors
Tagworks Pharmaceuticals has received authorization for its clinical Phase 0/1 study of TGW211, a radiopharmaceutical targeting HER2+ tumors. Initial patient data is anticipated in 2026.
third-news.com
October 16, 2025 at 3:43 PM
Tagworks Pharmaceuticals Announces Clinical Study Approval for TGW211 in Treating HER2+ Tumors#Netherlands#Nijmegen#Tagworks_Pharmaceuticals#HER2+_Cancer#TGW211
Jazz Pharmaceuticals Unveils Breakthrough Cancer Data at ASCO 2025 Conference#Ireland#Dublin#Jazz_Pharmaceuticals#Zepzelca#HER2+_Cancer
Jazz Pharmaceuticals Unveils Breakthrough Cancer Data at ASCO 2025 Conference
Jazz Pharmaceuticals presents transformative cancer research at ASCO 2025, showcasing advancements in Small Cell Lung Cancer therapies and more.
third-news.com
April 23, 2025 at 8:31 PM
Jazz Pharmaceuticals Unveils Breakthrough Cancer Data at ASCO 2025 Conference#Ireland#Dublin#Jazz_Pharmaceuticals#Zepzelca#HER2+_Cancer